Soligenix Inc Stock Price, News & Analysis

Soligenix, a late-stage biopharmaceutical company focused on rare diseases, announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The company will deliver an on-demand corporate presentation available on September 12 at 7 AM ET, accessible for 30 days for registered attendees. Management will also hold one-on-one meetings during the conference. Soligenix's key products include HyBryte™ for cutaneous T-cell lymphoma and several vaccine candidates targeting infectious diseases.

Soligenix, Inc. (Nasdaq: SNGX) announced that the FDA has awarded a $2.6 million Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage cutaneous T-cell lymphoma (CTCL). This grant will facilitate an open-label study designed to enroll approximately 50 patients across six centers. The study aims to assess treatment success based on a defined reduction in lesion severity. The initiative underscores the ongoing unmet medical need for effective CTCL therapies.

Soligenix, Inc. (Nasdaq: SNGX) reported its Q2 2022 financial results with revenues of $0.4 million, up from $0.2 million in Q2 2021. The company achieved key milestones, including FDA agreement on a pediatric study plan for HyBryte™ and IND clearance for a Phase 2a trial in psoriasis. Notably, Soligenix demonstrated 100% protection in non-human primates against lethal Ebola and Marburg viruses using a novel bivalent vaccine. The net loss for the quarter was $2.4 million, compared to $1.9 million in the previous year. The cash position remains strong at $20.2 million, supporting upcoming initiatives.

Soligenix, Inc. (Nasdaq: SNGX) announced FDA approval of its initial pediatric study plan for HyBryte™ intended for treating cutaneous T-cell lymphoma (CTCL). The company plans to request a full waiver of pediatric studies when submitting its new drug application (NDA) later this year. This agreement is a vital regulatory step toward commercialization. HyBryte™ is a novel photodynamic therapy utilizing synthetic hypericin, with a completed Phase 3 trial showing promising results against CTCL. Safety and efficacy profiles are favorable, positioning HyBryte™ as a potential front-line treatment.

Soligenix, Inc. (SNGX) has announced a strategic partnership with SERB Pharmaceuticals to exclusively license its ricin antigen for the development of a therapeutic treatment against ricin poisoning. This partnership aims to address a significant unmet medical need, as there are currently no therapeutic options available for ricin toxin exposure. Furthermore, Soligenix is advancing its own ricin vaccine, RiVax®, supported by over $30 million in government funding. The specific terms of the licensing agreement remain undisclosed.

Soligenix, Inc. (NASDAQ: SNGX) announced the publication of positive results from its Phase 3 FLASH study of HyBryte^™ in the treatment of cutaneous T-cell lymphoma (CTCL) in JAMA Dermatology. The study demonstrated a statistically significant reduction in lesion size, with 49% of patients achieving a response after 18 weeks of treatment. HyBryte^™ showed strong efficacy and safety, addressing the critical need for effective treatments in CTCL. The results highlight the potential of HyBryte^™ to set a new standard in CTCL therapy, indicating promising next steps for regulatory approval.

Soligenix, Inc. (Nasdaq: SNGX) announced FDA clearance of its IND application for a Phase 2a clinical trial of SGX302, targeting mild-to-moderate psoriasis. The trial aims to assess the safety and efficacy of topically-applied synthetic hypericin, with patient enrollment expected in Q4 2022. Previously, synthetic hypericin showed promising results in a Phase 1/2 trial for psoriasis. The global psoriasis market is projected to grow from $15 billion in 2020 to $40 billion by 2027, highlighting the potential impact of successful results from this trial.

Soligenix, Inc. (SNGX) announced a significant milestone: their bivalent vaccine demonstrated 100% protection in non-human primates against lethal Marburg and Sudan viruses. This subunit vaccine, developed in collaboration with the University of Hawaiʻi, features a thermostabilized formulation that can be stored at higher temperatures, enhancing public health response capabilities. The vaccine platform also shows promise for future health emergencies, including potential pandemic scenarios. Supported by NIH funding, the program continues to advance toward commercialization.

Soligenix, Inc. (Nasdaq: SNGX) announced a publication in the Journal Structure detailing the binding of its Innate Defense Regulator (IDR), dusquetide, to the p62 protein. Dusquetide shows anti-infective, anti-tumor, and anti-inflammatory properties, having reduced severe oral mucositis (SOM) rates in clinical trials. The Phase 3 study demonstrated significant results for its primary endpoint, supporting dusquetide's potential for HNC treatment. With a strong intellectual property position and ongoing research, Soligenix is exploring product opportunities for dusquetide and its analogs.